cancers-logo

Journal Browser

Journal Browser

Onco-Nephrology: From Molecular to Clinical Studies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 16 March 2026 | Viewed by 808

Special Issue Editor


E-Mail Website
Guest Editor
Department of Nephrology, Bicêtre Hospital, Le Kremlin-Bicêtre, France/Paris-Saclay Medical School, Le Kremlin-Bicêtre, France
Interests: nephrotic syndrome; immunology of transplantation; non-coding RNAs; cell death; protein structure; bioinformatics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The intersection of cancer and kidney diseases has emerged as a critical area of medical specialization over the last decade. This rapidly evolving field addresses the complex bidirectional relationship between oncological and renal conditions, becoming a major focus for nephrology consultations and an integral part of comprehensive cancer care.

Onco-nephrology encompasses a wide range of clinical scenarios, including acute kidney injury, chronic kidney disease, electrolyte disorders, and glomerular diseases associated with malignancies or cancer therapies. It also addresses the increased cancer risk in patients with kidney disease, particularly transplant recipients.

As cancer treatments advance, including conventional chemotherapy, targeted therapies, immunotherapies, and cellular therapies, the need for specialized expertise in this area has grown exponentially. Specialists in this field play a crucial role in managing renal complications of cancer and its treatments, optimizing care strategies, and improving patient outcomes.

Moreover, this discipline aims to ensure that patients with renal disease receive the same cancer treatment opportunities as the general population. It bridges the gap between nephrology and oncology, supporting clinical decision-making and addressing the unique challenges presented by the intersection of these fields.

This Special Issue explores the latest advancements in this crucial area, from molecular studies to clinical applications, highlighting its growing significance in modern medicine.

Prof. Dr. Hans Kristian Lorenzo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute kidney injury in oncology
  • chronic kidney disease and cancer
  • paraneoplastic glomerulonephritis
  • immunotherapy-related nephrotoxicity
  • tumor lysis syndrome
  • nephrotoxicity of chemotherapeutic agents
  • DNA damage
  • epigenetic modifications
  • molecular pathways in cancer-associated kidney injury
  • biomarkers for early detection of kidney injury

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 1415 KB  
Review
Small Nucleolar RNAs as Emerging Players in Cancer Biology and Precision Medicine
by Hans Kristian Lorenzo
Cancers 2025, 17(23), 3847; https://doi.org/10.3390/cancers17233847 - 30 Nov 2025
Viewed by 253
Abstract
Small nucleolar RNAs (snoRNAs) constitute a class of non-coding RNAs traditionally associated with ribosomal RNA modification. However, recent research has revealed that these molecules participate in a wide range of cellular processes with significant implications for cancer biology. This review examines the emerging [...] Read more.
Small nucleolar RNAs (snoRNAs) constitute a class of non-coding RNAs traditionally associated with ribosomal RNA modification. However, recent research has revealed that these molecules participate in a wide range of cellular processes with significant implications for cancer biology. This review examines the emerging evidence on snoRNA dysregulation in various tumor types, where they can function as both oncogenes and tumor suppressors. We analyze the multiple molecular mechanisms through which snoRNAs contribute to malignant transformation, including the generation of specialized ribosomes, alternative splicing regulation, epigenetic modulation, and post-transcriptional regulatory functions. We discuss the potential of snoRNAs as non-invasive biomarkers for cancer diagnosis and prognosis, as well as emerging strategies for their utilization as therapeutic targets. The integration of these findings positions snoRNAs as fundamental players in oncogenesis and opens new avenues for the development of clinical tools in precision cancer medicine. Full article
(This article belongs to the Special Issue Onco-Nephrology: From Molecular to Clinical Studies)
Show Figures

Figure 1

Back to TopTop